Newsletter Signup | Join Community
The c-Met inhibitor Capmatinib is a promising novel precision cancer medicine for the treatment of EGFR + NSCLC.
The WHO classifies air pollution as a carcinogen & ample evidence is emerging on it overall negative health consequences
Tecentriq® Improves NSCLC survival when combined with Avastin & chemotherapy Regardless of PD-L1 Status.
Alcensa, Xalkori, and several other precision cancer medicines target ALK positive lung cancer and improve treatment.
Dana-Farber Cancer Institute’s Dr. Jackman M. D. discusses the latest advances in the management of lung cancer
Research suggests that the symptoms, type, and treatment of lung cancer is different in non-smokers than smokers.
Research suggests the key to avoiding lung cancer is to stop smoking, avoid Radon and eat cruciferous vegetables!
What is the evidence and current recommendations for lung cancer screening?
Development of precision cancer medicines, immunotherapy, genomic testing are proceeding with great speed - Stay Current
Better Results in NSCLC with Higher Dose of ALK Inhibitor
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…